-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network January 29 - The Joint Procurement Office on January 15, 2021 officially released the fourth batch of national collection documents, the document states that "the filing deadline for filing materials is February 3rd", the industry generally believes that if the relevant enterprises can be evaluated before this time node can get tickets.
meters of intranet statistics, from the release of documents so far, a total of 13 products "line sprint", of which 4 varieties of competition is extremely fierce, a new round of price war is about to start.
Table 1: Reviewed after January 15, 2021 / As same as the evaluation of the product situation (by status start time statistics) Source: Minet 2.0MED China Drug Review Database ibuprofen oral normal release agent type, tygrelo oral regular release agent type, ammonia bromoso injection, Parexib injection four varieties have now been evaluated the number of enterprises more than 10, the competition is extremely fierce. in 2019, the end-user sales of
-based public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) exceeded 1.5 billion yuan, leading AstraZenecon in the market, accounting for more than 90%.
East Sunshine Medicine, Xinlitai, Yangzijiang, Zhengda Tianqing, Haizheng, Shi medicine and other domestic giants have been mo fist rub, AstraZeneca can hold the market? Ammonia bromoso injections in 2019 in China's public medical institutions terminal sales of nearly 6 billion yuan, Grigg Ingham market share in about 20%, the domestic generic drug companies between the competition is quite fierce, at present, Colum, Bbett and other domestic star pharmaceutical companies have been "tickets."
Parrisheb injections in China's public medical institutions in 2019 terminal sales of nearly 2 billion yuan, Pfizer 2019 market share of 60%, the first half of 2020 fell to 46.71 percent, Haizheng, Yangzijiang, Yuandong Biological, Osaikang, Nanjing Zhengda Tianqing, Colum, Qilu and other ready.
source: CDE official website, Minet database review data statistics as of January 28, 2021, if there are errors, please point out.